BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference

Core Insights - BriaCell Therapeutics Corp. will present three posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting from April 5-10 in San Diego, CA [1] Group 1: Poster Presentations - Poster 1 focuses on the efficacy of the Bria-IMT regimen in inducing regression of CNS metastasis, scheduled for April 9, 2024 [1] - Poster 2 discusses the efficacy and safety of SV-BR-1-GM after progression on ADC in metastatic breast cancer patients, also on April 9, 2024 [1] - Poster 3 presents the Bria-OTS immunotherapy platform, which aims to harness gene-modified tumor cells for precision anti-tumor responses, scheduled for April 10, 2024 [1] Group 2: Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care [2]